Alimera Sciences (ALIM) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ALIM Stock Forecast

Alimera Sciences stock forecast is as follows: an average price target of $5.75 (represents a 3.79% upside from ALIM’s last price of $5.54) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

ALIM Price Target

The average price target for Alimera Sciences (ALIM) is $5.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $5.50. This represents a potential 3.79% upside from ALIM's last price of $5.54.

ALIM Analyst Ratings

Hold

According to 9 Wall Street analysts, Alimera Sciences's rating consensus is 'Hold'. The analyst rating breakdown for ALIM stock is 1 'Strong Buy' (11.11%), 2 'Buy' (22.22%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

Alimera Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 25, 2024	Yi Chen	H.C. Wainwright	$6.00	$5.54	8.30%	8.30%
Jun 24, 2024	Chase Knickerbocker	Craig-Hallum	$5.50	$5.54	-0.72%	-0.72%
Jul 28, 2022		H.C. Wainwright	$9.00	$5.49	63.93%	62.45%
May 10, 2022		H.C. Wainwright	$8.00	$5.05	58.42%	44.40%

The latest Alimera Sciences stock forecast, released on Jun 25, 2024 by Yi Chen from H.C. Wainwright, set a price target of $6.00, which represents a 8.30% increase from the stock price at the time of the forecast ($5.54), and a 8.30% increase from ALIM last price ($5.54).

Alimera Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$5.75
Last Closing Price	$5.54	$5.54	$5.54
Upside/Downside	-100.00%	-100.00%	3.79%

In the current month, the average price target of Alimera Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alimera Sciences's last price of $5.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 25, 2024	Alliance Global Partners	Buy	Neutral	Downgrade
Jun 25, 2024	H.C. Wainwright		Neutral	Downgrade
Jun 24, 2024	Craig-Hallum		Hold	Downgrade
Jun 12, 2023	Raymond James		Strong Buy	Upgrade
Jun 12, 2023	Credit Suisse		Neutral	Downgrade
Jun 12, 2023	Morgan Stanley		Underweight	Downgrade
Jun 12, 2023	BMO Capital		Market Perform	Downgrade
Jun 12, 2023	Scotiabank		Outperform	Upgrade
Jun 12, 2023	William Blair		Outperform	Upgrade
Jun 12, 2023	Alliance Global Partners		Buy	Upgrade

Alimera Sciences's last stock rating was published by Alliance Global Partners on Jun 25, 2024. The company Downgrade its ALIM rating from "Buy" to "Neutral".

Alimera Sciences Financial Forecast

Alimera Sciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$26.31M	$23.36M	$17.54M	$13.55M	$14.03M	$13.60M	$14.60M	$11.90M	$13.96M	$12.15M	$21.70M	$11.21M	$13.77M	$12.47M	$10.04M	$14.54M	$17.35M	$12.85M
Avg Forecast	$35.90M	$31.80M	$32.20M	$27.90M	$33.03M	$29.97M	$29.57M	$25.93M	$29.90M	$27.43M	$25.74M	$22.25M	$24.33M	$22.70M	$20.47M	$12.30M	$14.63M	$15.05M	$13.14M	$12.53M	$13.40M	$12.37M	$16.04M	$11.40M	$13.43M	$10.89M	$6.58M	$14.09M	$14.99M	$12.79M
High Forecast	$35.90M	$31.80M	$32.20M	$27.90M	$33.03M	$29.97M	$29.57M	$25.93M	$29.90M	$27.43M	$25.74M	$22.25M	$24.33M	$22.70M	$20.47M	$12.30M	$14.63M	$15.05M	$13.14M	$12.53M	$13.40M	$12.37M	$16.04M	$11.40M	$13.43M	$10.89M	$6.58M	$14.09M	$14.99M	$12.79M
Low Forecast	$35.90M	$31.80M	$32.20M	$27.90M	$33.03M	$29.97M	$29.57M	$25.93M	$29.90M	$27.43M	$25.74M	$22.25M	$24.33M	$22.70M	$20.47M	$12.30M	$14.63M	$15.05M	$13.14M	$12.53M	$13.40M	$12.37M	$16.04M	$11.40M	$13.43M	$10.89M	$6.58M	$14.09M	$14.99M	$12.79M
# Analysts	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.08%	1.03%	0.86%	1.10%	0.96%	0.90%	1.11%	0.95%	1.04%	0.98%	1.35%	0.98%	1.03%	1.15%	1.52%	1.03%	1.16%	1.00%

Alimera Sciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $22.25M, with a low forecast of $22.25M, and a high forecast of $22.25M. ALIM's average Quarter revenue forecast represents a -15.44% decrease compared to the company's last Quarter revenue of $26.31M (Dec 23).

Alimera Sciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$3.76M	$-6.24M	$-14.17M	$-2.62M	$-1.43M	$-2.75M	$-1.30M	$-3.46M	$-2.12M	$-2.34M	$10.19M	$-1.67M	$1.01M	$1.35M	$-505.00K	$791.00K	$2.15M	$-1.16M
Avg Forecast	$-292.06K	$-258.70K	$-261.96K	$-226.98K	$-268.74K	$-243.79K	$-240.53K	$-210.98K	$-243.24K	$-223.16K	$-209.41K	$-4.80M	$-197.96K	$-184.67K	$-166.50K	$-3.79M	$-1.52M	$-122.41K	$-106.87K	$-3.00M	$-109.05K	$-100.64K	$-130.49K	$-1.39M	$-109.29K	$-88.61K	$-53.56K	$1.03M	$-121.98K	$-104.03K
High Forecast	$-292.06K	$-258.70K	$-261.96K	$-226.98K	$-268.74K	$-243.79K	$-240.53K	$-210.98K	$-243.24K	$-223.16K	$-209.41K	$-3.84M	$-197.96K	$-184.67K	$-166.50K	$-3.03M	$-1.22M	$-122.41K	$-106.87K	$-2.40M	$-109.05K	$-100.64K	$-130.49K	$-1.11M	$-109.29K	$-88.61K	$-53.56K	$1.23M	$-121.98K	$-104.03K
Low Forecast	$-292.06K	$-258.70K	$-261.96K	$-226.98K	$-268.74K	$-243.79K	$-240.53K	$-210.98K	$-243.24K	$-223.16K	$-209.41K	$-5.76M	$-197.96K	$-184.67K	$-166.50K	$-4.55M	$-1.83M	$-122.41K	$-106.87K	$-3.60M	$-109.05K	$-100.64K	$-130.49K	$-1.67M	$-109.29K	$-88.61K	$-53.56K	$821.17K	$-121.98K	$-104.03K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-19.01%	33.76%	85.12%	0.69%	0.93%	22.44%	12.20%	1.15%	19.41%	23.28%	-78.05%	1.20%	-9.26%	-15.25%	9.43%	0.77%	-17.58%	11.18%

1 analysts predict ALIM's average Quarter EBITDA for Mar 24 to be $-4.80M, with a high of $-3.84M and a low of $-5.76M. This is -227.42% lower than Alimera Sciences's previous annual EBITDA (Dec 23) of $3.76M.

Alimera Sciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-3.78M	$-1.35M	$-10.03M	$-8.30M	$-3.78M	$-5.26M	$-3.12M	$-7.76M	$-4.11M	$-4.18M	$7.57M	$-3.65M	$-977.00K	$-618.00K	$-2.55M	$-1.20M	$498.00K	$-3.14M
Avg Forecast	$6.53M	$3.26M	$3.26M	$-543.84K	$5.98M	$1.90M	$1.63M	$-1.36M	$1.99M	$-543.84K	$-1.99M	$-7.32M	$1.09M	$6.53M	$271.92K	$-5.79M	$-2.96M	$-21.75M	$-36.44M	$-4.57M	$-22.84M	$-28.55M	$57.65M	$-3.04M	$-2.36M	$-18.22M	$-67.98M	$-1.55M	$-16.10M	$-29.91M
High Forecast	$6.53M	$3.26M	$3.26M	$-543.84K	$5.98M	$1.90M	$1.63M	$-1.36M	$1.99M	$-543.84K	$-1.99M	$-5.86M	$1.09M	$6.53M	$271.92K	$-4.63M	$-2.37M	$-21.75M	$-36.44M	$-3.66M	$-22.84M	$-28.55M	$58.97M	$-2.43M	$-2.36M	$-18.22M	$-67.98M	$-1.24M	$-16.10M	$-29.91M
Low Forecast	$6.53M	$3.26M	$3.26M	$-543.84K	$5.98M	$1.90M	$1.63M	$-1.36M	$1.99M	$-543.84K	$-1.99M	$-8.78M	$1.09M	$6.53M	$271.92K	$-6.94M	$-3.55M	$-21.75M	$-36.44M	$-5.49M	$-22.84M	$-28.55M	$56.32M	$-3.65M	$-2.36M	$-18.22M	$-67.98M	$-1.87M	$-16.10M	$-29.91M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-3.48%	-0.21%	-36.88%	1.43%	1.28%	0.24%	0.09%	1.70%	0.18%	0.15%	0.13%	1.20%	0.41%	0.03%	0.04%	0.77%	-0.03%	0.10%

Alimera Sciences's average Quarter net income forecast for Sep 21 is $-28.55M, with a range of $-28.55M to $-28.55M. ALIM's average Quarter net income forecast represents a -477.41% decrease compared to the company's last Quarter net income of $7.57M (Jun 21).

Alimera Sciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$14.15M	$11.55M	$10.81M	$9.97M	$9.10M	$9.86M	$9.81M	$10.09M	$10.37M	$8.56M	$8.69M	$8.23M	$8.44M	$7.38M	$7.36M	$8.85M	$10.31M	$9.56M
Avg Forecast	$23.32M	$20.65M	$20.91M	$18.12M	$21.46M	$19.46M	$19.20M	$16.84M	$19.42M	$17.82M	$16.72M	$12.41M	$15.80M	$14.74M	$13.29M	$9.81M	$7.47M	$9.77M	$8.53M	$7.75M	$8.71M	$8.03M	$10.42M	$6.86M	$8.73M	$7.07M	$4.28M	$11.49M	$9.74M	$8.31M
High Forecast	$23.32M	$20.65M	$20.91M	$18.12M	$21.46M	$19.46M	$19.20M	$16.84M	$19.42M	$17.82M	$16.72M	$14.89M	$15.80M	$14.74M	$13.29M	$11.77M	$8.96M	$9.77M	$8.53M	$9.30M	$8.71M	$8.03M	$10.42M	$8.23M	$8.73M	$7.07M	$4.28M	$13.79M	$9.74M	$8.31M
Low Forecast	$23.32M	$20.65M	$20.91M	$18.12M	$21.46M	$19.46M	$19.20M	$16.84M	$19.42M	$17.82M	$16.72M	$9.92M	$15.80M	$14.74M	$13.29M	$7.85M	$5.97M	$9.77M	$8.53M	$6.20M	$8.71M	$8.03M	$10.42M	$5.49M	$8.73M	$7.07M	$4.28M	$9.19M	$9.74M	$8.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	0.78%	0.81%	1.02%	1.22%	1.01%	1.15%	1.30%	1.19%	1.07%	0.83%	1.20%	0.97%	1.04%	1.72%	0.77%	1.06%	1.15%

Alimera Sciences's average Quarter SG&A projection for Mar 24 is $12.41M, based on 1 Wall Street analysts, with a range of $9.92M to $14.89M. The forecast indicates a -12.31% fall compared to ALIM last annual SG&A of $14.15M (Dec 23).

Alimera Sciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.07	$-0.04	$-1.24	$-1.18	$-0.54	$-0.75	$-0.45	$-1.11	$-0.59	$-0.60	$1.03	$-0.63	$-0.18	$-0.12	$-0.51	$-0.24	$0.08	$-0.60
Avg Forecast	$0.12	$0.06	$0.06	$-0.01	$0.11	$0.04	$0.03	$-0.03	$0.04	$-0.01	$-0.04	$-0.06	$0.02	$0.12	$0.01	$-0.52	$-0.34	$-0.40	$-0.67	$-0.74	$-0.42	$-0.53	$1.06	$-0.54	$-0.04	$-0.34	$-1.25	$-0.40	$-0.30	$-0.55
High Forecast	$0.12	$0.06	$0.06	$-0.01	$0.11	$0.04	$0.03	$-0.03	$0.04	$-0.01	$-0.04	$-0.06	$0.02	$0.12	$0.01	$-0.52	$-0.34	$-0.40	$-0.67	$-0.74	$-0.42	$-0.53	$1.08	$-0.54	$-0.04	$-0.34	$-1.25	$-0.40	$-0.30	$-0.55
Low Forecast	$0.12	$0.06	$0.06	$-0.01	$0.11	$0.04	$0.03	$-0.03	$0.04	$-0.01	$-0.04	$-0.06	$0.02	$0.12	$0.01	$-0.52	$-0.34	$-0.40	$-0.67	$-0.74	$-0.42	$-0.53	$1.04	$-0.54	$-0.04	$-0.34	$-1.25	$-0.40	$-0.30	$-0.55
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-3.48%	-0.35%	-248.00%	2.29%	1.61%	1.88%	0.67%	1.49%	1.40%	1.14%	0.97%	1.17%	4.15%	0.36%	0.41%	0.61%	-0.27%	1.09%

According to 1 Wall Street analysts, Alimera Sciences's projected average Quarter EPS for Sep 21 is $-0.53, with a low estimate of $-0.53 and a high estimate of $-0.53. This represents a -150.97% decrease compared to ALIM previous annual EPS of $1.03 (Jun 21).

Alimera Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
ORGO	Organogenesis	$3.57	$5.00	40.06%	Buy
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy

ALIM Forecast FAQ

Is Alimera Sciences a good buy?

No, according to 9 Wall Street analysts, Alimera Sciences (ALIM) is considered a 'Hold'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of ALIM's total ratings.

What is ALIM's price target?

Alimera Sciences (ALIM) average price target is $5.75 with a range of $5.5 to $6, implying a 3.79% from its last price of $5.54. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Alimera Sciences stock go up soon?

According to Wall Street analysts' prediction for ALIM stock, the company can go up by 3.79% (from the last price of $5.54 to the average price target of $5.75), up by 8.30% based on the highest stock price target, and down by -0.72% based on the lowest stock price target.

Can Alimera Sciences stock reach $8?

ALIM's average twelve months analyst stock price target of $5.75 does not support the claim that Alimera Sciences can reach $8 in the near future.

What are Alimera Sciences's analysts' financial forecasts?

Alimera Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.5M (high $118.5M, low $118.5M), average EBITDA is $-964K (high $-964K, low $-964K), average net income is $8.16M (high $8.16M, low $8.16M), average SG&A $76.97M (high $76.97M, low $76.97M), and average EPS is $0.15 (high $0.15, low $0.15). ALIM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $127.8M (high $127.8M, low $127.8M), average EBITDA is $-1.04M (high $-1.04M, low $-1.04M), average net income is $12.51M (high $12.51M, low $12.51M), average SG&A $83.01M (high $83.01M, low $83.01M), and average EPS is $0.23 (high $0.23, low $0.23).

Did the ALIM's actual financial results beat the analysts' financial forecasts?

Based on Alimera Sciences's last annual report (Dec 2023), the company's revenue was $80.75M, beating the average analysts forecast of $79.8M by 1.20%. Apple's EBITDA was $6.82M, missing the average prediction of $-4.341M by -257.01%. The company's net income was $-20.132M, missing the average estimation of $2.1M by -1058.96%. Apple's SG&A was $46.48M, missing the average forecast of $53.65M by -13.37%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.37 by 113.51%. In terms of the last quarterly report (Dec 2023), Alimera Sciences's revenue was $26.31M, beating the average analysts' forecast of $24.33M by 8.11%. The company's EBITDA was $3.76M, missing the average prediction of $-198K by -2001.39%. Alimera Sciences's net income was $-3.781M, missing the average estimation of $1.09M by -447.62%. The company's SG&A was $14.15M, missing the average forecast of $15.8M by -10.49%. Lastly, the company's EPS was $-0.0695, missing the average prediction of $0.02 by -447.50%